Comprehensive Stock Comparison
Compare Virax Biolabs Group Limited (VRAX) vs Cardio Diagnostics Holdings, Inc. (CDIO) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  CDIO | 104.5% revenue growth vs VRAX's -96.0% |
| Quality / Margins |  VRAX | -78.6% net margin vs CDIO's -415.2% |
| Stability / Safety | VRAX | Beta 1.24 vs CDIO's 2.02, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CDIO | -62.1% vs VRAX's -84.6% |
| Efficiency (ROA) | CDIO | -74.5% ROA vs VRAX's -199.1%, ROIC -222.7% vs -273.2% |
Who Each Stock Is For
Income & stability
VRAXbeta 1.24
Growth exposure
CDIORev growth 104.5%, EPS growth 53.0%, 3Y rev CAGR 238.3%
Long-term compounding (10Y)
CDIO-98.2% 10Y total return vs VRAX's -99.9%
Sleep-well-at-night portfolio
VRAXLower volatility, beta 1.24, Low D/E 6.9%, current ratio 7.27x
Defensive / Recession hedge
VRAXBeta 1.24, current ratio 7.27x
Business Model
What each company does and how it makes money
Virax Biolabs Group is a biotechnology company focused on viral disease prevention, detection, and management through diagnostic test kits and medical technology products. It generates revenue primarily from selling diagnostic tests—including rapid antibody, antigen, and PCR tests under the ViraxClear brand—and medical/PPE products under the ViraxCare brand, distributed through clinics, pharmacies, hospitals, and an online platform. The company's competitive advantage lies in its integrated portfolio spanning diagnostics and protective equipment for viral diseases, serving both healthcare institutions and corporate clients across multiple international markets.
Cardio Diagnostics develops and commercializes epigenetics-based clinical tests for cardiovascular disease risk assessment. It generates revenue primarily from sales of its Epi+Gen CHD test—a three-year symptomatic coronary heart disease risk assessment—to healthcare providers and through laboratory services. The company's moat lies in its proprietary epigenetic technology platform that offers more personalized cardiovascular risk prediction than traditional methods.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VRAX 2CDIO 2VRAX5/6 metricsVRAX2/3 metricsCDIO5/9 metricsCDIO6/6 metricsVRAX leads in 2 of 6 categories (Financial Metrics, Valuation Metrics). CDIO leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Financial Metrics (TTM)
VRAX is the larger business by revenue, generating $162,750 annually — 10.3x CDIO's $15,782. VRAX is the more profitable business, keeping -78.6% of every revenue dollar as net income compared to CDIO's -415.2%. On growth, CDIO holds the edge at -56.6% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VRAXVirax Biolabs Gro… | CDIOCardio Diagnostic… |
|---|---|---|
| RevenueTrailing 12 months | $162,750 | $15,782 |
| EBITDAEarnings before interest/tax | -$12M | -$6M |
| Net IncomeAfter-tax profit | -$13M | -$7M |
| Free Cash FlowCash after capex | -$13M | -$6M |
| Gross MarginGross profit ÷ Revenue | -1.5% | -10.3% |
| Operating MarginEBIT ÷ Revenue | -77.8% | -414.2% |
| Net MarginNet income ÷ Revenue | -78.6% | -415.2% |
| FCF MarginFCF ÷ Revenue | -77.3% | -379.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | -98.3% | -56.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +55.6% | -15.3% |
Valuation Metrics
| Metric | VRAXVirax Biolabs Gro… | CDIOCardio Diagnostic… |
|---|---|---|
| Market CapShares × price | $2M | $141M |
| Enterprise ValueMkt cap + debt − cash | -$2M | $135M |
| Trailing P/EPrice ÷ TTM EPS | -0.11x | -0.57x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 245.06x | 4054.38x |
| Price / BookPrice ÷ Book value/share | 0.12x | 14.80x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
CDIO delivers a -80.4% return on equity — every $100 of shareholder capital generates $-80 in annual profit, vs $-2 for VRAX. VRAX carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to CDIO's 0.10x. On the Piotroski fundamental quality scale (0–9), CDIO scores 4/9 vs VRAX's 1/9, reflecting mixed financial health.
| Metric | VRAXVirax Biolabs Gro… | CDIOCardio Diagnostic… |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | -80.4% |
| ROA (TTM)Return on assets | -199.1% | -74.5% |
| ROICReturn on invested capital | -2.7% | -2.2% |
| ROCEReturn on capital employed | -111.4% | -123.0% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 |
| Debt / EquityFinancial leverage | 0.07x | 0.10x |
| Net DebtTotal debt minus cash | -$4M | -$7M |
| Cash & Equiv.Liquid assets | $4M | $8M |
| Total DebtShort + long-term debt | $377,004 | $969,863 |
| Interest CoverageEBIT ÷ Interest expense | -149.04x | -418.04x |
Total Returns (with DRIP)
A $10,000 investment in CDIO five years ago would be worth $179 today (with dividends reinvested), compared to $11 for VRAX. Over the past 12 months, CDIO leads with a -62.1% total return vs VRAX's -84.6%. The 3-year compound annual growth rate (CAGR) favors CDIO at -68.0% vs VRAX's -68.4% — a key indicator of consistent wealth creation.
| Metric | VRAXVirax Biolabs Gro… | CDIOCardio Diagnostic… |
|---|---|---|
| YTD ReturnYear-to-date | -45.6% | +85.2% |
| 1-Year ReturnPast 12 months | -84.6% | -62.1% |
| 3-Year ReturnCumulative with dividends | -96.8% | -96.7% |
| 5-Year ReturnCumulative with dividends | -99.9% | -98.2% |
| 10-Year ReturnCumulative with dividends | -99.9% | -98.2% |
| CAGR (3Y)Annualised 3-year return | -68.4% | -68.0% |
Risk & Volatility
VRAX is the less volatile stock with a 1.24 beta — it tends to amplify market swings less than CDIO's 2.02 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDIO currently trades 30.2% from its 52-week high vs VRAX's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VRAXVirax Biolabs Gro… | CDIOCardio Diagnostic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 2.02x |
| 52-Week HighHighest price in past year | $1.58 | $17.39 |
| 52-Week LowLowest price in past year | $0.19 | $0.97 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +30.2% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 64.3 |
| Avg Volume (50D)Average daily shares traded | 320K | 3.3M |
Analyst Outlook
| Metric | VRAXVirax Biolabs Gro… | CDIOCardio Diagnostic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jul 22 | Mar 26 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | 100 | 0.12 | -99.9% |
| Cardio Diagnostics … (CDIO) | 100 | 1.74 | -98.3% |
Cardio Diagnostics … (CDIO) returned -98% over 5 years vs Virax Biolabs Group… (VRAX)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | $99876.00 | $6331.00 | -93.7% |
| Cardio Diagnostics … (CDIO) | $0.00 | $34890.00 | — |
Virax Biolabs Group Limited's revenue grew from $0M (2020) to $0M (2025) — a -42.4% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -8.0% | -957.4% | -11835.7% |
| Cardio Diagnostics … (CDIO) | -688.6% | -240.3% | +65.1% |
Virax Biolabs Group Limited's net margin went from -8% (2020) to -957% (2025).
Chart 4EPS Growth — 10 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -0.7 | -1.95 | -178.6% |
| Cardio Diagnostics … (CDIO) | -0.06 | -9.3 | -14522.6% |
Virax Biolabs Group Limited's EPS grew from $-0.70 (2020) to $-1.95 (2025).
Chart 5Free Cash Flow — 5 Years
Virax Biolabs Group Limited generated $-5M FCF in 2025 (-776% vs 2021). Cardio Diagnostics Holdings, Inc. generated $-5M FCF in 2024 (-672% vs 2021).
VRAX vs CDIO: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — VRAX or CDIO?
Over the past 5 years, Cardio Diagnostics Holdings, Inc. (CDIO) delivered a total return of -98.2%, compared to -99.9% for Virax Biolabs Group Limited (VRAX). A $10,000 investment in CDIO five years ago would be worth approximately $179 today (assuming dividends reinvested). Over 10 years, the gap is even starker: CDIO returned -98.2% versus VRAX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — VRAX or CDIO?
By beta (market sensitivity over 5 years), Virax Biolabs Group Limited (VRAX) is the lower-risk stock at 1.24β versus Cardio Diagnostics Holdings, Inc.'s 2.02β — meaning CDIO is approximately 62% more volatile than VRAX relative to the S&P 500. On balance sheet safety, Virax Biolabs Group Limited (VRAX) carries a lower debt/equity ratio of 7% versus 10% for Cardio Diagnostics Holdings, Inc. — giving it more financial flexibility in a downturn.
03Which has better profit margins — VRAX or CDIO?
Cardio Diagnostics Holdings, Inc. (CDIO) is the more profitable company, earning -240.3% net margin versus -957.4% for Virax Biolabs Group Limited — meaning it keeps -240.3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CDIO leads at -239.8% versus -973.4% for VRAX. At the gross margin level — before operating expenses — CDIO leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — VRAX or CDIO?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is VRAX or CDIO better for a retirement portfolio?
For long-horizon retirement investors, Virax Biolabs Group Limited (VRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.24)). Cardio Diagnostics Holdings, Inc. (CDIO) carries a higher beta of 2.02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VRAX: -99.9%, CDIO: -98.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between VRAX and CDIO?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.